MicroRNA 100: a context dependent miRNA in prostate cancer
Carregando...
Citações na Scopus
31
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Citação
CLINICS, v.68, n.6, p.797-802, 2013
Resumo
OBJECTIVE: MicroRNAs are noncoding RNA molecules involved in the development and progression of tumors. We have found that miRNA-100 is underexpressed in metastatic prostate cancer compared to localized disease. Conversely higher levels of miR-100 are related to biochemical recurrence after surgery. This suggests that miR-100 may be a context-dependent miRNA, acting as oncogene or tumor suppressor miRNA. Our aim is to demonstrate the role of miR-100 in the control of predicted target genes in prostate cancer cell lines. METHODS: Cell lines DU145 and PC3 were transfected with miR-100, antimiR-100 and after 24 h and 48 h of exposure, qRT-PCR and western blot were performed for mTOR, FGFR3, THAP2, SMARCA5 and BAZ2A. RESULTS: There was reduction in mTOR (p = 0.025), THAP2 (p = 0.038), SMARCA5 (p = 0.001) and BAZ2A (p = 0.006) mRNA expression in DU145 cells after exposure to miR-100. In PC3 cells, mTOR expression was decreased by miR-100 (p = 0.01). There was a reduction in the expression levels of proteins encoded by studied genes, ranging from 34% to 69%. CONCLUSIONS: We demonstrate that miR-100 is a context-dependent miRNA controlling BAZ2, mTOR, FGFR3, SMARCA5 and THAP2 that might be involved in PC progression. The elucidation of the roles of miRNAs in tumors is important because they can be used as therapeutic targets in the future.
Palavras-chave
Prostate Cancer, Micro RNA, miR-100, Gene Expression, Protein Expression, PCR, Western Blot
Referências
- Bantis A, 2005, J EXP CLIN CANC RES, V24, P273
- Bessiere D, 2008, J BIOL CHEM, V283, P4352, DOI 10.1074/jbc.M707537200
- Borre M, 1998, PROSTATE, V36, P244
- Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707
- Hisaoka M, 2011, GENE CHROMOSOME CANC, V50, P137, DOI 10.1002/gcc.20837
- Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
- Leite KRM, 2011, J UROLOGY, V185, P1118, DOI 10.1016/j.juro.2010.10.035
- Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002
- Rowbotham SP, 2011, MOL CELL, V42, P285, DOI 10.1016/j.molcel.2011.02.036
- Uzoh CC, 2009, BJU INT, V104, P556, DOI 10.1111/j.1464-410X.2009.08411.x
- Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/mrc839
- Yoshimoto M, 2012, MODERN PATHOLOGY OFF
- Zhou YG, 2002, EMBO J, V21, P4632, DOI 10.1093/emboj/cdf460